Tranexamic Acid NDC 59651-839

NDC codes

FDA NDC Directory

Product NDC (as listed)59651-839Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59651-0839Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59651-839-30	59651083930	30 TABLET in 1 BOTTLE (59651-839-30)Marketed from Dec 4, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tranexamic Acid
Generic name (nonproprietary): tranexamic acid
Active ingredients: Tranexamic acid — 650 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Aurobindo Pharma Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 205133
Marketing start: Dec 4, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Fibrinolysis (Physiologic effect)
Identifiers: Product ID 59651-839_773eb919-7d48-4ba2-af58-aa169f0ea75fSPL ID 773eb919-7d48-4ba2-af58-aa169f0ea75fSPL set ID 773eb919-7d48-4ba2-af58-aa169f0ea75fRxCUI 883826UNII 6T84R30KC1
Pharmacologic class: Antifibrinolytic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459651083930 followed by a unit qualifier and the quantity

Package 59651-0839-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 7, 2023.

Indications (excerpt from the label)

Tranexamic acid tablets are indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential [see Clinical Studies (14) ] . Tranexamic acid tablets are an antifibrinolytic indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 205133

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 205133
Product	Strength	Form · route	Labeler	Product NDC
Tranexamic Acid	Tranexamic acid 650 mg/1	TabletOral	NorthStar Rx LLC	72603-818